Literature DB >> 19278428

Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.

Loren E Clarke1, Thomas J Fountaine, Jeannie Hennessy, Richard D Bruggeman, Jennie T Clarke, David T Mauger, Klaus F Helm.   

Abstract

BACKGROUND: Cdc7 is a serine-threonine kinase required for initiation of DNA replication that may play a role in the development and progression of melanoma.
MATERIALS AND METHODS: Tissue microarrays containing 40 melanomas, 40 Spitz tumors and 30 nevi were constructed. Staining for Cdc7 was scored semiquantitatively according to intensity and extent, and the values were converted into composite scores.
RESULTS: Nodular melanomas, atypical Spitz tumors and superficial spreading melanomas had the highest scores (nodular melanomas, 3.67; atypical Spitz tumors, 2.78 and superficial spreading melanomas, 2.44). Typical Spitz nevi, dysplastic nevi and ordinary nevi had the lowest scores. Cdc7 expression in melanomas differed significantly from non-Spitz nevi (p < 0.001). The difference was also significant when invasive melanomas were compared with dysplastic nevi (p < 0.005) and when invasive melanomas were compared with non-atypical Spitz nevi (p < 0.001). However, there was no significant difference between invasive melanomas and atypical Spitz tumors (p = 0.69) or between dysplastic nevi and ordinary nevi (p = 0.73).
CONCLUSION: Cdc7 expression differs significantly among cutaneous melanocytic neoplasms and can be evaluated by routine immunohistochemical methods. The results suggest that differences in Cdc7 expression may account for some of the differences between malignant melanomas and benign melanocytic nevi.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19278428     DOI: 10.1111/j.1600-0560.2008.01077.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  12 in total

1.  Spitz nevi and other Spitzoid lesions part I. Background and diagnoses.

Authors:  Su Luo; Alireza Sepehr; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2011-12       Impact factor: 11.527

2.  MiR-200a with CDC7 as a direct target declines cell viability and promotes cell apoptosis in Wilm's tumor via Wnt/β-catenin signaling pathway.

Authors:  Xiu-Ling Liang; Yu-Long Wang; Pei-Rong Wang
Journal:  Mol Cell Biochem       Date:  2021-02-18       Impact factor: 3.396

Review 3.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  The role of Dbf4-dependent protein kinase in DNA polymerase ζ-dependent mutagenesis in Saccharomyces cerevisiae.

Authors:  Luis N Brandão; Rebecca Ferguson; Irma Santoro; Sue Jinks-Robertson; Robert A Sclafani
Journal:  Genetics       Date:  2014-05-28       Impact factor: 4.562

5.  Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies.

Authors:  Ji Qian; Hongliang Liu; Sheng Wei; Zhensheng Liu; Yangkai Li; Li-E Wang; Wei V Chen; Christopher I Amos; Jeffrey E Lee; Mark M Iles; Matthew H Law; Anne E Cust; Jennifer H Barrett; Grant W Montgomery; John Taylor; Julia A Newton Bishop; Stuart Macgregor; D Timothy Bishop; Graham J Mann; Nicholas K Hayward; Qingyi Wei
Journal:  Pigment Cell Melanoma Res       Date:  2013-03-27       Impact factor: 4.693

6.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

7.  Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer.

Authors:  Nathaniel Melling; Johanna Muth; Ronald Simon; Carsten Bokemeyer; Luigi Terracciano; Guido Sauter; Jakob Robert Izbicki; Andreas Holger Marx
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

8.  Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway.

Authors:  Shaimaa A Gad; Hamdy E A Ali; Rofaida Gaballa; Rania M Abdelsalam; Mourad Zerfaoui; Hamed I Ali; Salwa H Salama; Sanaa A Kenawy; Emad Kandil; Zakaria Y Abd Elmageed
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

9.  ATR-Chk1-APC/CCdh1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass under replication stress.

Authors:  Masayuki Yamada; Kenji Watanabe; Martin Mistrik; Eva Vesela; Iva Protivankova; Niels Mailand; MyungHee Lee; Hisao Masai; Jiri Lukas; Jiri Bartek
Journal:  Genes Dev       Date:  2013-11-15       Impact factor: 11.361

Review 10.  Roles of Sorcin in Drug Resistance in Cancer: One Protein, Many Mechanisms, for a Novel Potential Anticancer Drug Target.

Authors:  Theo Battista; Annarita Fiorillo; Valerio Chiarini; Ilaria Genovese; Andrea Ilari; Gianni Colotti
Journal:  Cancers (Basel)       Date:  2020-04-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.